Open-label trial · 2026
Psilocybin paired with cognitive behavioural therapy for depression: a 16-person pilot trial
- Original title
- Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial.
- Authors
- Weintraub MJ, Jeffrey JK, Ichinose MC, et al.
- Journal
- Journal of affective disorders, 2026
- Molecules
- Psilocybin
- Conditions
- Depression
- Participants
- 16
- Evidence grade
- Very low
- Source
- Read the original paper
The question
Can a structured, manual-based form of talk therapy — cognitive behavioural therapy (CBT) — be combined with psilocybin treatment for major depression, and is it acceptable to patients and clinicians?
What they did
Sixteen adults with major depressive disorder and at least moderately severe symptoms took part. Everyone received the same programme: two psilocybin doses (10 mg, then 25 mg one month later) woven into 12 CBT sessions over four months. Depression symptoms, day-to-day functioning, and thinking and emotion patterns were measured at the start, at the end of treatment, and three months later. There was no placebo or comparison group.
What they found
All 16 participants stayed in the study through the full seven months. Participants and clinicians rated the combined treatment as highly acceptable, and no serious adverse events were reported. By the end of treatment, 13 of 16 people showed at least a 25 percent improvement in depression symptoms, as judged by independent assessors, and 9 were in full remission. Improvements in depression and psychosocial functioning were still present at the three-month follow-up, and changes in depression severity tracked with improvements in emotion regulation and in positive and negative thinking patterns.
The fine print
This was a small pilot with 16 people, every one of whom received the same treatment — there was no placebo or alternative-therapy group, so it cannot show that psilocybin, the CBT, or simply time and attention drove the change. Nobody was blinded, which can inflate reported benefit. Follow-up ended three months after treatment, so longer-term outcomes are unknown, and this summary is based on the abstract alone.
What it means
Combining psilocybin with a standard, manualized form of talk therapy appears practical and was well tolerated in a small group, but randomized comparisons are needed before anything can be said about how well it works relative to other approaches.
Evidence grade: Very low. A small open-label pilot with only 16 people, no control or comparison group, and no blinding, so improvements cannot be separated from expectation or natural recovery.
This summary is based on the study’s published abstract.